Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.
Rediti M, Venet D, Joaquin Garcia A, Maetens M, Vincent D, Majjaj S, El-Abed S, Di Cosimo S, Ueno T, Izquierdo M, Piccart M, Pusztai L, Loi S, Salgado R, Viale G, Rothé F, Sotiriou C.
Rediti M, et al. Among authors: ueno t.
Nat Commun. 2024 Nov 29;15(1):10402. doi: 10.1038/s41467-024-54621-3.
Nat Commun. 2024.
PMID: 39613746
Free PMC article.